Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 99Y4J | IM |
Shortness of breath; fever; body pain; This non-serious case was reported by a other health professional and described the occurrence of shortness of breath in a 51-year-old male patient who received Herpes zoster (Shingrix) (batch number 99Y4J, expiry date 27-OCT-2026) for prophylaxis. On 12-NOV-2024, the patient received Shingrix (intramuscular) .5 ml. On 12-NOV-2024, less than a day after receiving Shingrix, the patient experienced shortness of breath (Verbatim: Shortness of breath), fever (Verbatim: fever) and general body pain (Verbatim: body pain). On 13-NOV-2024, the outcome of the shortness of breath, fever and general body pain were resolved (duration 1 day). It was unknown if the reporter considered the shortness of breath, fever and general body pain to be related to Shingrix. It was unknown if the company considered the shortness of breath, fever and general body pain to be related to Shingrix. Additional Information: GSK Receipt Date: 28-JAN-2025 The patient was seen in the clinic on 13th November 2024. They were advised to be seen in emergency room. The patient was transported to emergency room, and labs and imaging were completed, all of which were normal. the patient was given medication and sent home.
Test Date: 20241113; Test Name: imaging; Result Unstructured Data: (Test Result:normal value,Unit:unknown,Normal Low:,Normal High:); Test Date: 20241113; Test Name: labs; Result Unstructured Data: (Test Result:normal value,Unit:unknown,Normal Low:,Normal High:)